Search

Search results

179 results found

Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.

Roblin, Xavier, Stéphane Nancey, Konstantinos Papamichael, Gérard Duru, Mathurin Flamand, Sandy Kwiatek, Adam Cheifetz, Nicole Fabien, Mathilde Barrau, and Stephane Paul. 2024. “Higher Serum Infliximab Concentrations Following Subcutaneous Dosing Are Associated With Deep Remission in Patients With Inflammatory Bowel Disease.”. Journal of Crohn’s & Colitis 18 (5): 679-85.

Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?

De Mello, Munique Kurtz, Natália Sousa Freitas Queiroz, and Konstantinos Papamichael. 2024. “Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?”. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 22 (1): 200-201.

Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial.

Cheifetz, Adam S, Niels Vande Casteele, Zhongya Wang, Marla C Dubinsky, and Konstantinos Papamichael. 2023. “Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn’s Disease: A Post Hoc Analysis of the REACH Trial.”. The American Journal of Gastroenterology 118 (3): 485-90.